Cybin (NYSE:CYBN – Get Free Report) is one of 443 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Cybin to similar companies based on the strength of its dividends, institutional ownership, profitability, valuation, risk, analyst recommendations and earnings.
Profitability
This table compares Cybin and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Cybin | N/A | -109.05% | -97.85% |
Cybin Competitors | -8,581.17% | -107.37% | -23.32% |
Earnings & Valuation
This table compares Cybin and its competitors gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Cybin | N/A | -$35.93 million | -45.40 |
Cybin Competitors | $148.01 million | -$13.34 million | 154.31 |
Institutional and Insider Ownership
17.9% of Cybin shares are held by institutional investors. Comparatively, 29.2% of shares of all “Biotechnology” companies are held by institutional investors. 15.0% of Cybin shares are held by insiders. Comparatively, 25.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Cybin and its competitors, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Cybin | 0 | 0 | 3 | 0 | 3.00 |
Cybin Competitors | 738 | 2180 | 5069 | 56 | 2.55 |
Cybin presently has a consensus target price of $50.50, suggesting a potential upside of 456.17%. As a group, “Biotechnology” companies have a potential upside of 7.90%. Given Cybin’s stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than its competitors.
Risk and Volatility
Cybin has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Cybin’s competitors have a beta of 1.26, indicating that their average share price is 26% more volatile than the S&P 500.
Summary
Cybin competitors beat Cybin on 9 of the 13 factors compared.
About Cybin
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.